Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025

Reuters

11/04

Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025

Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567378-en) on November 03, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2580210133"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580210133\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580210133?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 00:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580210133","market":"nz","top_or_hot":-1,"title":"Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567378-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 00:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567378-en) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9Z6n4R:1","article_id":"2580210133","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580210133","pubTimestamp":1762185918,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology  Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI , a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","01548":"金斯瑞生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1583":"高瓴概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4505":"高瓴资本持仓","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","LEGN":"传奇生物","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"传奇生物在ASH 2025上公布新的CAR-T和同种异体细胞治疗数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":0.9,"LEGN":0.9,"NDAQ":0.9},"content_text":"Legend Biotech Unveils New CAR-T and Allogeneic Cell Therapy Data at ASH 2025\n    \n\n        Legend Biotech Corporation has announced ten presentations at the upcoming 67th American Society of Hematology $(ASH)$ Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida. The company will present two oral presentations and seven posters on CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), a BCMA-targeted CAR-T cell therapy for multiple myeloma. CARVYKTI is currently approved for patients with multiple myeloma who have received at least one prior line of therapy and is commercially available in 14 countries. In addition to the CARVYKTI data, Legend Biotech will deliver an oral presentation on Lucar-G39D, its investigational anti-CD20/CD19 dual-CAR allogeneic gamma delta T cell therapy, being studied in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The results from these studies will be presented at the ASH meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567378-en) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}